发明名称 Pharmaceutical preparations of human RPE cells and uses thereof
摘要 <p>This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.</p>
申请公布号 GB201220511(D0) 申请公布日期 2012.12.26
申请号 GB20120020511 申请日期 2012.11.14
申请人 ADVANCED CELL TECHNOLOGY INC 发明人
分类号 主分类号
代理机构 代理人
主权项
地址